GT Biopharma, Inc. (GTBP)
USD 2.3
(-1.29%)
USD 2.3
(-1.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.63 Million USD | 32.61% |
| 2022 | 5 Million USD | -51.24% |
| 2021 | 10.25 Million USD | -70.77% |
| 2020 | 35.09 Million USD | 78.09% |
| 2019 | 19.7 Million USD | 40.47% |
| 2018 | 14.02 Million USD | 423.67% |
| 2017 | 2.67 Million USD | -85.86% |
| 2016 | 18.94 Million USD | -69.38% |
| 2015 | 61.88 Million USD | 103.16% |
| 2014 | 30.46 Million USD | 370.02% |
| 2013 | 6.48 Million USD | -1.23% |
| 2012 | 6.56 Million USD | 25.47% |
| 2011 | 5.23 Million USD | -7.5% |
| 2010 | 5.65 Million USD | -20.46% |
| 2009 | 7.1 Million USD | 66.46% |
| 2008 | 4.27 Million USD | 32.28% |
| 2007 | 3.22 Million USD | -58.63% |
| 2006 | 7.8 Million USD | 82.8% |
| 2005 | 4.26 Million USD | 59.25% |
| 2004 | 2.68 Million USD | 145.2% |
| 2003 | 1.09 Million USD | 42.5% |
| 2002 | 767 Thousand USD | -35.44% |
| 2001 | 1.18 Million USD | -23.45% |
| 2000 | 1.55 Million USD | -37.8% |
| 1999 | 2.49 Million USD | -37.63% |
| 1998 | 4 Million USD | -31.03% |
| 1997 | 5.8 Million USD | 65.71% |
| 1996 | 3.5 Million USD | -37.5% |
| 1995 | 5.6 Million USD | 24.44% |
| 1994 | 4.5 Million USD | 1400.0% |
| 1993 | 300 Thousand USD | -50.0% |
| 1992 | 600 Thousand USD | 200.0% |
| 1991 | 200 Thousand USD | 0.0% |
| 1990 | 200 Thousand USD | -60.0% |
| 1989 | 500 Thousand USD | 66.67% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 3.75 Million USD | -18.28% |
| 2024 Q1 | 4.6 Million USD | -30.65% |
| 2023 Q4 | 6.63 Million USD | 7.98% |
| 2023 Q2 | 6.38 Million USD | -9.27% |
| 2023 Q1 | 7.03 Million USD | 40.6% |
| 2023 Q3 | 6.14 Million USD | -3.73% |
| 2023 FY | 6.63 Million USD | 32.61% |
| 2022 Q1 | 9.65 Million USD | -5.94% |
| 2022 Q3 | 5.11 Million USD | -41.39% |
| 2022 Q2 | 8.73 Million USD | -9.53% |
| 2022 Q4 | 5 Million USD | -2.25% |
| 2022 FY | 5 Million USD | -51.24% |
| 2021 Q4 | 10.25 Million USD | 161.58% |
| 2021 FY | 10.25 Million USD | -70.77% |
| 2021 Q2 | 3.27 Million USD | -9.65% |
| 2021 Q1 | 3.62 Million USD | -89.67% |
| 2021 Q3 | 3.92 Million USD | 19.72% |
| 2020 Q2 | 28.56 Million USD | 35.04% |
| 2020 Q1 | 21.15 Million USD | 7.33% |
| 2020 Q3 | 30.69 Million USD | 7.46% |
| 2020 Q4 | 35.09 Million USD | 14.34% |
| 2020 FY | 35.09 Million USD | 78.09% |
| 2019 Q4 | 19.7 Million USD | 5.0% |
| 2019 Q1 | 15.52 Million USD | 10.65% |
| 2019 FY | 19.7 Million USD | 40.47% |
| 2019 Q2 | 16.73 Million USD | 7.78% |
| 2019 Q3 | 18.76 Million USD | 12.18% |
| 2018 Q4 | 14.02 Million USD | 6.1% |
| 2018 Q3 | 13.22 Million USD | 47.71% |
| 2018 Q2 | 8.95 Million USD | 76.36% |
| 2018 Q1 | 5.07 Million USD | 89.47% |
| 2018 FY | 14.02 Million USD | 423.67% |
| 2017 FY | 2.67 Million USD | -85.86% |
| 2017 Q1 | 18.34 Million USD | -3.17% |
| 2017 Q3 | 2.8 Million USD | -86.08% |
| 2017 Q2 | 20.12 Million USD | 9.69% |
| 2017 Q4 | 2.67 Million USD | -4.39% |
| 2016 FY | 18.94 Million USD | -69.38% |
| 2016 Q3 | 17.36 Million USD | 7.24% |
| 2016 Q2 | 16.19 Million USD | -20.05% |
| 2016 Q1 | 20.25 Million USD | -67.27% |
| 2016 Q4 | 18.94 Million USD | 9.12% |
| 2015 Q4 | 61.88 Million USD | 151.6% |
| 2015 FY | 61.88 Million USD | 103.16% |
| 2015 Q1 | 51.35 Million USD | 68.6% |
| 2015 Q2 | 23.03 Million USD | -55.15% |
| 2015 Q3 | 24.59 Million USD | 6.8% |
| 2014 Q2 | 7.01 Million USD | 3.07% |
| 2014 Q1 | 6.8 Million USD | 5.05% |
| 2014 Q4 | 30.46 Million USD | 162.29% |
| 2014 Q3 | 11.61 Million USD | 65.51% |
| 2014 FY | 30.46 Million USD | 370.02% |
| 2013 Q3 | 6.03 Million USD | 4.74% |
| 2013 Q1 | 5.4 Million USD | -17.6% |
| 2013 Q2 | 5.75 Million USD | 6.49% |
| 2013 Q4 | 6.48 Million USD | 7.46% |
| 2013 FY | 6.48 Million USD | -1.23% |
| 2012 Q3 | 6.32 Million USD | -3.55% |
| 2012 Q4 | 6.56 Million USD | 3.73% |
| 2012 FY | 6.56 Million USD | 25.47% |
| 2012 Q1 | 5.42 Million USD | 3.8% |
| 2012 Q2 | 6.55 Million USD | 20.81% |
| 2011 FY | 5.23 Million USD | -7.5% |
| 2011 Q1 | 7.16 Million USD | 26.65% |
| 2011 Q2 | 5.79 Million USD | -19.03% |
| 2011 Q3 | 5.27 Million USD | -8.99% |
| 2011 Q4 | 5.23 Million USD | -0.89% |
| 2010 FY | 5.65 Million USD | -20.46% |
| 2010 Q4 | 5.65 Million USD | 1.07% |
| 2010 Q3 | 5.59 Million USD | -9.51% |
| 2010 Q2 | 6.18 Million USD | -23.1% |
| 2010 Q1 | 8.03 Million USD | 13.1% |
| 2009 Q1 | 4.52 Million USD | 5.95% |
| 2009 FY | 7.1 Million USD | 66.46% |
| 2009 Q4 | 7.1 Million USD | 37.27% |
| 2009 Q3 | 5.17 Million USD | 4.33% |
| 2009 Q2 | 4.96 Million USD | 9.7% |
| 2008 Q1 | 4.07 Million USD | 26.18% |
| 2008 FY | 4.27 Million USD | 32.28% |
| 2008 Q4 | 4.27 Million USD | -3.06% |
| 2008 Q3 | 4.4 Million USD | 6.04% |
| 2008 Q2 | 4.15 Million USD | 1.99% |
| 2007 Q1 | 5.15 Million USD | -33.89% |
| 2007 FY | 3.22 Million USD | -58.63% |
| 2007 Q3 | 4.12 Million USD | -3.57% |
| 2007 Q2 | 4.28 Million USD | -17.02% |
| 2007 Q4 | 3.22 Million USD | -21.78% |
| 2006 Q4 | 7.8 Million USD | 46.35% |
| 2006 FY | 7.8 Million USD | 82.8% |
| 2006 Q2 | 4.98 Million USD | 1.01% |
| 2006 Q1 | 4.93 Million USD | 15.58% |
| 2006 Q3 | 5.33 Million USD | 6.98% |
| 2005 FY | 4.26 Million USD | 59.25% |
| 2005 Q4 | 4.26 Million USD | 691.84% |
| 2005 Q1 | 949 Thousand USD | -64.59% |
| 2005 Q2 | 725 Thousand USD | -23.6% |
| 2005 Q3 | 539 Thousand USD | -25.66% |
| 2004 Q3 | 2.96 Million USD | -2.47% |
| 2004 FY | 2.68 Million USD | 145.2% |
| 2004 Q1 | 1.1 Million USD | 1.19% |
| 2004 Q4 | 2.68 Million USD | -9.55% |
| 2004 Q2 | 3.03 Million USD | 174.68% |
| 2003 Q2 | 1.07 Million USD | 26.45% |
| 2003 Q1 | 847 Thousand USD | 10.43% |
| 2003 FY | 1.09 Million USD | 42.5% |
| 2003 Q3 | 1.03 Million USD | -3.36% |
| 2003 Q4 | 1.09 Million USD | 5.6% |
| 2002 Q1 | 1.06 Million USD | -10.52% |
| 2002 FY | 767 Thousand USD | -35.44% |
| 2002 Q4 | 767 Thousand USD | 9.57% |
| 2002 Q3 | 700 Thousand USD | -23.83% |
| 2002 Q2 | 919 Thousand USD | -13.55% |
| 2001 Q1 | 1.36 Million USD | -12.37% |
| 2001 FY | 1.18 Million USD | -23.45% |
| 2001 Q4 | 1.18 Million USD | 7.61% |
| 2001 Q3 | 1.1 Million USD | -25.1% |
| 2001 Q2 | 1.47 Million USD | 8.38% |
| 2000 Q3 | 1.57 Million USD | -5.51% |
| 2000 Q4 | 1.55 Million USD | -1.65% |
| 2000 Q2 | 1.67 Million USD | -7.02% |
| 2000 FY | 1.55 Million USD | -37.8% |
| 2000 Q1 | 1.79 Million USD | -28.02% |
| 1999 Q3 | 2.1 Million USD | 0.0% |
| 1999 Q2 | 2.1 Million USD | -4.55% |
| 1999 Q1 | 2.2 Million USD | -45.0% |
| 1999 Q4 | 2.49 Million USD | 18.81% |
| 1999 FY | 2.49 Million USD | -37.63% |
| 1998 Q4 | 4 Million USD | -4.76% |
| 1998 FY | 4 Million USD | -31.03% |
| 1998 Q3 | 4.2 Million USD | -4.55% |
| 1998 Q1 | 5.6 Million USD | -3.45% |
| 1998 Q2 | 4.4 Million USD | -21.43% |
| 1997 Q4 | 5.8 Million USD | 75.76% |
| 1997 Q3 | 3.3 Million USD | 13.79% |
| 1997 Q2 | 2.9 Million USD | -34.09% |
| 1997 Q1 | 4.4 Million USD | 25.71% |
| 1997 FY | 5.8 Million USD | 65.71% |
| 1996 FY | 3.5 Million USD | -37.5% |
| 1996 Q2 | 2.3 Million USD | -61.67% |
| 1996 Q4 | 3.5 Million USD | 20.69% |
| 1996 Q3 | 2.9 Million USD | 26.09% |
| 1996 Q1 | 6 Million USD | 7.14% |
| 1995 Q1 | 4.7 Million USD | 4.44% |
| 1995 FY | 5.6 Million USD | 24.44% |
| 1995 Q3 | 4.2 Million USD | -4.55% |
| 1995 Q4 | 5.6 Million USD | 33.33% |
| 1995 Q2 | 4.4 Million USD | -6.38% |
| 1994 FY | 4.5 Million USD | 1400.0% |
| 1994 Q2 | 1.3 Million USD | 160.0% |
| 1994 Q1 | 500 Thousand USD | 66.67% |
| 1994 Q4 | 4.5 Million USD | 0.0% |
| 1994 Q3 | 4.5 Million USD | 246.15% |
| 1993 Q4 | 300 Thousand USD | -50.0% |
| 1993 FY | 300 Thousand USD | -50.0% |
| 1993 Q2 | 200 Thousand USD | -66.67% |
| 1993 Q1 | 600 Thousand USD | 0.0% |
| 1993 Q3 | 600 Thousand USD | 200.0% |
| 1992 Q4 | 600 Thousand USD | 100.0% |
| 1992 Q2 | 200 Thousand USD | 200.0% |
| 1992 Q1 | -200 Thousand USD | -200.0% |
| 1992 FY | 600 Thousand USD | 200.0% |
| 1992 Q3 | 300 Thousand USD | 50.0% |
| 1991 Q3 | 600 Thousand USD | 200.0% |
| 1991 Q2 | 200 Thousand USD | 100.0% |
| 1991 Q1 | 100 Thousand USD | -50.0% |
| 1991 Q4 | 200 Thousand USD | -66.67% |
| 1991 FY | 200 Thousand USD | 0.0% |
| 1990 Q4 | 200 Thousand USD | 100.0% |
| 1990 Q3 | 100 Thousand USD | -80.0% |
| 1990 Q2 | 500 Thousand USD | -16.67% |
| 1990 Q1 | 600 Thousand USD | 20.0% |
| 1990 FY | 200 Thousand USD | -60.0% |
| 1989 Q2 | 500 Thousand USD | 0.0% |
| 1989 Q4 | 500 Thousand USD | 0.0% |
| 1989 Q3 | 500 Thousand USD | 0.0% |
| 1989 FY | 500 Thousand USD | 66.67% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 98.025% |
| Alkermes plc | 933.53 Million USD | 99.289% |
| Agenus Inc. | 462.29 Million USD | 98.565% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 99.836% |
| Aptorum Group Limited | 5.25 Million USD | -26.181% |
| Ardelyx, Inc. | 130.76 Million USD | 94.927% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 98.613% |
| Bicycle Therapeutics plc | 224.41 Million USD | 97.044% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 94.906% |
| ChromaDex Corporation | 26.5 Million USD | 74.977% |
| Chimerix, Inc. | 19.74 Million USD | 66.407% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | 81.144% |
| Caribou Biosciences, Inc. | 72.56 Million USD | 90.859% |
| CRISPR Therapeutics AG | 346.76 Million USD | 98.087% |
| Precision BioSciences, Inc. | 140.92 Million USD | 95.293% |
| Dyadic International, Inc. | 2.34 Million USD | -183.383% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | 59.214% |
| Fortress Biotech, Inc. | 165.93 Million USD | 96.003% |
| Lantern Pharma Inc. | 2.73 Million USD | -142.108% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | 90.72% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -87.972% |
| Incyte Corporation | 1.59 Billion USD | 99.583% |
| IO Biotech, Inc. | 17.55 Million USD | 62.218% |
| Jaguar Health, Inc. | 45.86 Million USD | 85.538% |
| Novavax, Inc. | 2.57 Billion USD | 99.742% |
| Janux Therapeutics, Inc. | 36.05 Million USD | 81.605% |
| Opthea Limited | 264.6 Million USD | 97.493% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 94.925% |
| ContextLogic Inc. | 206 Million USD | 96.78% |
| MiMedx Group, Inc. | 96.33 Million USD | 93.114% |
| Pyxis Oncology, Inc. | 48.02 Million USD | 86.188% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -87.963% |
| NextCure, Inc. | 14.99 Million USD | 55.771% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -64.102% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | 0.659% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | 85.808% |
| Vaxcyte, Inc. | 167.44 Million USD | 96.039% |
| PDS Biotechnology Corporation | 33.25 Million USD | 80.057% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 97.18% |
| Pharming Group N.V. | 244.07 Million USD | 97.282% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | 44.363% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 94.809% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -0.389% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -0.389% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 91.953% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | 0.151% |
| Acelyrin, Inc. | 86.35 Million USD | 92.319% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -410.529% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | 53.87% |
| Summit Therapeutics Inc. | 125.25 Million USD | 94.704% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | 30.024% |
| Senti Biosciences, Inc. | 52.57 Million USD | 87.383% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | 90.356% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 95.622% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -239.11% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -396.644% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 97.076% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | 29.188% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 97.084% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 98.659% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 39.225% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | 75.89% |
| Psyence Biomedical Ltd. | 12.1 Million USD | 45.203% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 98.637% |
| Immix Biopharma, Inc. | 3.72 Million USD | -78.221% |
| Keros Therapeutics, Inc. | 37.81 Million USD | 82.458% |
| MEI Pharma, Inc. | 8.35 Million USD | 20.61% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 77.139% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 98.092% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 95.453% |
| Fortress Biotech, Inc. | 165.93 Million USD | 96.003% |
| Precigen, Inc. | 41.64 Million USD | 84.072% |
| Clearside Biomedical, Inc. | 49.93 Million USD | 86.715% |
| AlloVir, Inc. | 45.01 Million USD | 85.265% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 94.911% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 95.187% |
| ImmuCell Corporation | 18.81 Million USD | 64.746% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | 76.5% |
| Onconetix, Inc. | 23.18 Million USD | 71.386% |
| PureTech Health plc | 125.58 Million USD | 94.718% |
| VYNE Therapeutics Inc. | 8.95 Million USD | 25.888% |
| Elevation Oncology, Inc. | 34.28 Million USD | 80.652% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -171.288% |
| Seer, Inc. | 39.36 Million USD | 83.15% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | 89.273% |
| Innoviva, Inc. | 568.55 Million USD | 98.833% |
| Aadi Bioscience, Inc. | 27.22 Million USD | 75.639% |
| ESSA Pharma Inc. | 3.49 Million USD | -89.782% |
| GlycoMimetics, Inc. | 6.9 Million USD | 3.898% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 97.491% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 97.564% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | 92.106% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | 32.136% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | 75.586% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -105.625% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | 91.008% |
| Aptose Biosciences Inc. | 15.8 Million USD | 58.042% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | 39.917% |
| Soligenix, Inc. | 7.27 Million USD | 8.824% |
| Century Therapeutics, Inc. | 175.94 Million USD | 96.23% |
| Kura Oncology, Inc. | 51.66 Million USD | 87.161% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 94.531% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -60.489% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -0.289% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 97.374% |
| Autolus Therapeutics plc | 263.9 Million USD | 97.487% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | 36.72% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | 92.536% |
| Eterna Therapeutics Inc. | 46.89 Million USD | 85.857% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 98.12% |
| GRI Bio, Inc. | 2.69 Million USD | -145.94% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -719.309% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | 78.666% |
| IGM Biosciences, Inc. | 220.17 Million USD | 96.987% |
| INmune Bio, Inc. | 18.86 Million USD | 64.834% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 97.414% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | 75.103% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -144.003% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -102.209% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | 88.653% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | 93.102% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 97.494% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 99.194% |
| Verastem, Inc. | 71.18 Million USD | 90.682% |
| Abeona Therapeutics Inc. | 49.17 Million USD | 86.512% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | 82.806% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | 86.444% |
| Histogen Inc. | 5.69 Million USD | -16.43% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -51.245% |
| Surrozen, Inc. | 8.14 Million USD | 18.564% |
| Organovo Holdings, Inc. | 2.74 Million USD | -141.376% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -2013.376% |
| Ovid Therapeutics Inc. | 56.22 Million USD | 88.204% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 59.829% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | 87.02% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -702.177% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 94.766% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | 38.661% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 95.604% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -154.397% |
| Apollomics, Inc. | 14.15 Million USD | 53.134% |
| Amarin Corporation plc | 279.58 Million USD | 97.628% |
| Mesoblast Limited | 188.79 Million USD | 96.487% |
| Turnstone Biologics Corp. | 14.14 Million USD | 53.117% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 96.331% |
| Synaptogenix, Inc. | 5.52 Million USD | -19.957% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | 0.226% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 96.101% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | 22.486% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -277.434% |
| Exelixis, Inc. | 678.44 Million USD | 99.022% |
| Better Therapeutics, Inc. | 23.84 Million USD | 72.179% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 95.957% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 98.884% |
| NLS Pharmaceutics AG | 10.68 Million USD | 37.894% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -308.533% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 82.96% |
| Gritstone bio, Inc. | 125.91 Million USD | 94.732% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | 54.804% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -30.35% |
| Avid Bioservices, Inc. | 275.66 Million USD | 97.594% |
| Insmed Incorporated | 1.66 Billion USD | 99.601% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | 13.79% |
| MediWound Ltd. | 27.18 Million USD | 75.602% |
| OmniAb, Inc. | 87.4 Million USD | 92.411% |
| Alector, Inc. | 487.66 Million USD | 98.64% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 98.356% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | 64.0% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 82.714% |
| Zai Lab Limited | 240.17 Million USD | 97.238% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 98.947% |
| Aura Biosciences, Inc. | 29.22 Million USD | 77.305% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | 93.024% |
| Immunic, Inc. | 25.36 Million USD | 73.853% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | 90.42% |
| Veracyte, Inc. | 93.71 Million USD | 92.922% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -153.49% |
| FibroGen, Inc. | 585.72 Million USD | 98.868% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | 61.842% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -915.655% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -17.285% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 99.913% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | 19.09% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | 92.106% |
| TG Therapeutics, Inc. | 169.08 Million USD | 96.077% |
| Galecto, Inc. | 5.89 Million USD | -12.5% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 19.93% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 99.747% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | 76.986% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | 47.445% |
| XBiotech Inc. | 8.39 Million USD | 21.008% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | 54.804% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | 87.527% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 98.173% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | 75.327% |
| Theravance Biopharma, Inc. | 169 Million USD | 96.075% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 99.454% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 98.675% |
| Vaxxinity, Inc. | 30.94 Million USD | 78.565% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 99.318% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -9.98% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 99.11% |
| NexImmune, Inc. | 5.08 Million USD | -30.462% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -1685.974% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -115.718% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.907% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -28.695% |
| Scopus BioPharma Inc. | 7.45 Million USD | 11.019% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | 74.774% |
| Ainos, Inc. | 7.39 Million USD | 10.295% |
| Pluri Inc. | 34.11 Million USD | 80.555% |
| Prothena Corporation plc | 135.01 Million USD | 95.087% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 97.272% |
| Celularity Inc. | 102.92 Million USD | 93.556% |
| Rallybio Corporation | 9.43 Million USD | 29.705% |
| Cue Biopharma, Inc. | 24.44 Million USD | 72.866% |
| MeiraGTx Holdings plc | 319.99 Million USD | 97.927% |
| Omeros Corporation | 403.25 Million USD | 98.355% |
| Humacyte, Inc. | 114.67 Million USD | 94.216% |
| Immunocore Holdings plc | 228.15 Million USD | 97.093% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -36.062% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | 91.357% |
| Blueprint Medicines Corporation | 918.64 Million USD | 99.278% |
| CalciMedica, Inc. | 4.02 Million USD | -64.672% |
| Cabaletta Bio, Inc. | 17.45 Million USD | 61.993% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 95.697% |
| Scholar Rock Holding Corporation | 85.81 Million USD | 92.271% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 97.612% |
| Pulmatrix, Inc. | 15.96 Million USD | 58.448% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | 57.947% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | 73.043% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 97.355% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | 86.939% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 99.452% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 79.13% |
| Nutriband Inc. | 1.07 Million USD | -514.782% |
| Protara Therapeutics, Inc. | 10.63 Million USD | 37.619% |
| Vor Biopharma Inc. | 59.1 Million USD | 88.777% |
| Roivant Sciences Ltd. | 773.95 Million USD | 99.143% |
| Evogene Ltd. | 17.99 Million USD | 63.13% |
| ProKidney Corp. | 29.21 Million USD | 77.297% |
| Applied Therapeutics, Inc. | 71.97 Million USD | 90.785% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -840.874% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 99.649% |
| CorMedix Inc. | 11.91 Million USD | 44.342% |
| BioLineRx Ltd. | 50.7 Million USD | 86.918% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 95.562% |
| Galectin Therapeutics Inc. | 88.44 Million USD | 92.5% |
| Atai Life Sciences N.V. | 49.16 Million USD | 86.508% |
| Renovaro Biosciences Inc. | 31.15 Million USD | 78.708% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | 63.072% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 94.678% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -17.315% |
| MediciNova, Inc. | 3.89 Million USD | -70.446% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | 63.712% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -340.953% |
| GeoVax Labs, Inc. | 3.51 Million USD | -88.444% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 98.33% |
| Biomea Fusion, Inc. | 30.69 Million USD | 78.387% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 99.756% |
| Mereo BioPharma Group plc | 15.96 Million USD | 58.445% |
| Cullinan Oncology, Inc. | 31.2 Million USD | 78.741% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | 88.697% |
| Absci Corporation | 58.3 Million USD | 88.623% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | 65.177% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | 79.312% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | 91.011% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | 92.418% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | 80.358% |
| Allakos Inc. | 74.79 Million USD | 91.132% |
| Imunon, Inc. | 8.53 Million USD | 22.243% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | 70.521% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 94.223% |
| BioAtla, Inc. | 48.98 Million USD | 86.459% |
| NLS Pharmaceutics AG | 10.68 Million USD | 37.894% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -138.683% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 94.921% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | 53.338% |
| XOMA Corporation | 145.58 Million USD | 95.444% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | 80.297% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 90.353% |
| aTyr Pharma, Inc. | 31.59 Million USD | 79.008% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | 89.271% |
| Akero Therapeutics, Inc. | 44.96 Million USD | 85.249% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | 86.296% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -131.115% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | 18.693% |
| Akari Therapeutics, Plc | 4.58 Million USD | -44.699% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | 62.595% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 99.598% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -1542.206% |
| UroGen Pharma Ltd. | 243.52 Million USD | 97.276% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 97.934% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -140.191% |
| Orgenesis Inc. | 35.53 Million USD | 81.334% |
| Entera Bio Ltd. | 1.37 Million USD | -381.001% |
| GH Research PLC | 6.7 Million USD | 1.015% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | 2.456% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | 64.767% |
| Xencor, Inc. | 283.55 Million USD | 97.661% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -122.161% |
| Replimune Group, Inc. | 113.21 Million USD | 94.141% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -76.545% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | 93.593% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -1542.206% |
| Portage Biotech Inc. | 4.45 Million USD | -49.056% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -340.953% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | 71.223% |
| OncoCyte Corporation | 49.29 Million USD | 86.545% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -60.341% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -731.741% |
| Purple Biotech Ltd. | 10 Million USD | 33.703% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -14.639% |
| scPharmaceuticals Inc. | 57.26 Million USD | 88.416% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | 46.456% |
| HilleVax, Inc. | 78.9 Million USD | 91.594% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -31.347% |
| Tharimmune, Inc. | 1.81 Million USD | -265.445% |
| Genprex, Inc. | 3.25 Million USD | -103.828% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | 75.541% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -26.681% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -3119.903% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -1749.962% |
| OKYO Pharma Limited | 7.42 Million USD | 10.617% |
| Savara Inc. | 37.19 Million USD | 82.166% |
| Curis, Inc. | 57.61 Million USD | 88.487% |
| Daré Bioscience, Inc. | 26.32 Million USD | 74.808% |
| Carmell Therapeutics Corporation | 39.19 Million USD | 83.079% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -359.349% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | 68.14% |
| BeiGene, Ltd. | 2.23 Billion USD | 99.703% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 68.844% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 97.472% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | 68.821% |
| Erasca, Inc. | 78.61 Million USD | 91.562% |
| bluebird bio, Inc. | 424.62 Million USD | 98.438% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -912.282% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 99.649% |
| DBV Technologies S.A. | 42.8 Million USD | 84.502% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -912.282% |
| Moderna, Inc. | 4.57 Billion USD | 99.855% |
| Vincerx Pharma, Inc. | 6.99 Million USD | 5.175% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -300.543% |
| Molecular Templates, Inc. | 31.17 Million USD | 78.721% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | 61.142% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 98.872% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 94.673% |
| Spruce Biosciences, Inc. | 27.43 Million USD | 75.825% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | 81.805% |
| Cogent Biosciences, Inc. | 55.63 Million USD | 88.078% |
| MacroGenics, Inc. | 154.2 Million USD | 95.699% |
| RenovoRx, Inc. | 4.46 Million USD | -48.522% |
| Adicet Bio, Inc. | 37.12 Million USD | 82.131% |
| Prime Medicine, Inc. | 60.78 Million USD | 89.087% |
| Aditxt, Inc. | 28.53 Million USD | 76.752% |
| Adagene Inc. | 45.16 Million USD | 85.315% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -3570.705% |
| Quantum-Si incorporated | 26.63 Million USD | 75.093% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 99.049% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -118.016% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 94.23% |
| SciSparc Ltd. | 1.59 Million USD | -315.862% |
| Vericel Corporation | 127.7 Million USD | 94.806% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -19.194% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | 92.229% |
| Generation Bio Co. | 171.63 Million USD | 96.135% |
| Astria Therapeutics, Inc. | 11.55 Million USD | 42.571% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | 84.143% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 97.375% |
| Invivyd, Inc. | 51.71 Million USD | 87.173% |
| Relay Therapeutics, Inc. | 91.97 Million USD | 92.788% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -1.964% |
| Spero Therapeutics, Inc. | 75.49 Million USD | 91.214% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -549.657% |
| 2seventy bio, Inc. | 310.12 Million USD | 97.861% |
| ADMA Biologics, Inc. | 193.97 Million USD | 96.581% |
| Clene Inc. | 38.95 Million USD | 82.971% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | 81.643% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 97.419% |
| GeoVax Labs, Inc. | 3.51 Million USD | -88.444% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 96.514% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | 45.54% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 96.655% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | 45.608% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 86.213% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | 87.447% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 98.207% |
| Evaxion Biotech A/S | 17.61 Million USD | 62.35% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 95.878% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 95.67% |
| Trevena, Inc. | 48.26 Million USD | 86.256% |
| Surrozen, Inc. | 8.14 Million USD | 18.564% |
| Tyra Biosciences, Inc. | 21.59 Million USD | 69.285% |
| Cingulate Inc. | 10.36 Million USD | 35.98% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -141.2% |
| Unity Biotechnology, Inc. | 37.29 Million USD | 82.213% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -84.943% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | 49.559% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 97.909% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | 73.307% |
| Clearmind Medicine Inc. | 3.61 Million USD | -83.739% |
| Kronos Bio, Inc. | 54.2 Million USD | 87.762% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | 85.9% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | 70.856% |
| Viking Therapeutics, Inc. | 20.07 Million USD | 66.952% |
| Statera Biopharma, Inc. | 22.67 Million USD | 70.749% |
| ImmunityBio, Inc. | 1.09 Billion USD | 99.392% |
| Korro Bio, Inc. | 51.75 Million USD | 87.183% |
| Kineta, Inc. | 7.22 Million USD | 8.156% |
| BioVie Inc. | 9.7 Million USD | 31.634% |
| Codexis, Inc. | 49.94 Million USD | 86.72% |
| Celularity Inc. | 102.92 Million USD | 93.556% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | 93.108% |
| Celcuity Inc. | 51.45 Million USD | 87.108% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -1821.528% |
| Cibus, Inc. | 206.11 Million USD | 96.782% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | 84.384% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 74.817% |
| IN8bio, Inc. | 8.77 Million USD | 24.384% |
| Kodiak Sciences Inc. | 213.59 Million USD | 96.895% |
| Annexon, Inc. | 47.11 Million USD | 85.923% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | 92.592% |
| Assembly Biosciences, Inc. | 96.37 Million USD | 93.117% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | 51.545% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 99.745% |
| Eyenovia, Inc. | 19.78 Million USD | 66.467% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 96.254% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | 13.644% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | 72.476% |
| Arcellx, Inc. | 339.75 Million USD | 98.048% |
| Cardiff Oncology, Inc. | 11.89 Million USD | 44.251% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 97.299% |
| Regulus Therapeutics Inc. | 9.56 Million USD | 30.639% |
| Moolec Science SA | 13.94 Million USD | 52.436% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | 84.629% |
| Geron Corporation | 146.12 Million USD | 95.461% |
| LAVA Therapeutics N.V. | 50.53 Million USD | 86.874% |
| Royalty Pharma plc | 6.29 Billion USD | 99.895% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | 83.324% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -2153.011% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -169.603% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 96.493% |
| Humacyte, Inc. | 114.67 Million USD | 94.216% |
| Structure Therapeutics Inc. | 29.05 Million USD | 77.168% |
| 89bio, Inc. | 59.96 Million USD | 88.938% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | 74.935% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -454.599% |
| Genelux Corporation | 8.42 Million USD | 21.223% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | 3.253% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 95.134% |
| Notable Labs, Ltd. | 4.42 Million USD | -49.831% |
| Liquidia Corporation | 73.13 Million USD | 90.931% |
| Mustang Bio, Inc. | 17.61 Million USD | 62.353% |
| Immunovant, Inc. | 48.95 Million USD | 86.451% |
| Quantum-Si incorporated | 26.63 Million USD | 75.093% |
| Arbutus Biopharma Corporation | 38.38 Million USD | 82.719% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -113.761% |
| Vera Therapeutics, Inc. | 73.86 Million USD | 91.02% |
| Acasti Pharma Inc. | 11.55 Million USD | 42.606% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | 70.66% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -144.003% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | 82.013% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -386.704% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -8.809% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | 73.292% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | 71.39% |
| PepGen Inc. | 34.63 Million USD | 80.847% |
| Moleculin Biotech, Inc. | 12.14 Million USD | 45.38% |
| United Therapeutics Corporation | 1.18 Billion USD | 99.439% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | 5.026% |
| Solid Biosciences Inc. | 38.45 Million USD | 82.753% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | 22.486% |
| Immuneering Corporation | 12 Million USD | 44.763% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -2013.376% |
| Silo Pharma, Inc. | 1.56 Million USD | -322.681% |
| Belite Bio, Inc | 4.21 Million USD | -57.516% |
| XOMA Corporation | 145.58 Million USD | 95.444% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -173.188% |
| Bionomics Limited | 10.15 Million USD | 34.706% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | 69.136% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | 71.051% |
| uniQure N.V. | 624.01 Million USD | 98.937% |
| Cassava Sciences, Inc. | 14.19 Million USD | 53.272% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -3570.705% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 96.102% |
| Forte Biosciences, Inc. | 3.66 Million USD | -80.933% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -2445.446% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | 1.69% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | 13.644% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | 61.842% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | 37.235% |
| Altimmune, Inc. | 16.54 Million USD | 59.9% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 98.926% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | 71.051% |
| Compugen Ltd. | 55.77 Million USD | 88.108% |
| Peak Bio, Inc. | 20.75 Million USD | 68.039% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 93.995% |
| Benitec Biopharma Inc. | 4.96 Million USD | -33.676% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 95.798% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | 91.176% |
| Zura Bio Limited | 21.29 Million USD | 68.847% |
| PolyPid Ltd. | 17.46 Million USD | 62.028% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 94.099% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | 91.176% |
| Instil Bio, Inc. | 99.8 Million USD | 93.354% |
| argenx SE | 444.95 Million USD | 98.509% |
| Immunome, Inc. | 28.65 Million USD | 76.855% |
| Compass Therapeutics, Inc. | 8.33 Million USD | 20.439% |
| Verona Pharma plc | 58.84 Million USD | 88.727% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | 54.17% |
| Shattuck Labs, Inc. | 14.85 Million USD | 55.36% |
| CervoMed Inc. | 2.59 Million USD | -155.533% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -36.089% |
| Plus Therapeutics, Inc. | 12.73 Million USD | 47.919% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | 37.038% |
| Moolec Science SA | 13.94 Million USD | 52.436% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -183.038% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | 88.069% |
| AnaptysBio, Inc. | 364.28 Million USD | 98.179% |
| Design Therapeutics, Inc. | 11.95 Million USD | 44.522% |
| Leap Therapeutics, Inc. | 12.68 Million USD | 47.706% |
| NeurAxis, Inc. | 1.91 Million USD | -246.78% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | 82.961% |
| Lumos Pharma, Inc. | 13.33 Million USD | 50.251% |
| Achilles Therapeutics plc | 19.08 Million USD | 65.249% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | 54.17% |
| 180 Life Sciences Corp. | 5.38 Million USD | -23.125% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | 71.88% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | 70.856% |
| Nutriband Inc. | 1.07 Million USD | -514.782% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | 78.322% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | 54.29% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 98.347% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | 79.574% |
| MoonLake Immunotherapeutics | 13.04 Million USD | 49.169% |
| Palisade Bio, Inc. | 2.73 Million USD | -142.169% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -26.271% |
| Beam Therapeutics Inc. | 478.38 Million USD | 98.613% |
| Neurogene Inc. | 36.54 Million USD | 81.852% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 98.333% |
| AEON Biopharma, Inc. | 159.88 Million USD | 95.851% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | 86.08% |
| Sesen Bio, Inc. | 30.98 Million USD | 78.592% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | 74.45% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | 12.749% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 96.611% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 96.546% |
| Athira Pharma, Inc. | 30.05 Million USD | 77.932% |
| Vaccinex, Inc. | 5.94 Million USD | -11.629% |
| HCW Biologics Inc. | 15.05 Million USD | 55.933% |
| XOMA Corporation | 145.58 Million USD | 95.444% |
| Nektar Therapeutics | 267.04 Million USD | 97.516% |
| Arvinas, Inc. | 644.6 Million USD | 98.971% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | 62.595% |
| Merus N.V. | 102.15 Million USD | 93.507% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 95.468% |
| Quince Therapeutics, Inc. | 95.12 Million USD | 93.027% |
| Rezolute, Inc. | 11.73 Million USD | 43.472% |
| Clene Inc. | 38.95 Million USD | 82.971% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -132.951% |
| BeyondSpring Inc. | 48.26 Million USD | 86.258% |
| Synlogic, Inc. | 32.89 Million USD | 79.836% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | 54.609% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -305.936% |
| Peak Bio, Inc. | 20.75 Million USD | 68.039% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | 89.548% |
| Krystal Biotech, Inc. | 39.71 Million USD | 83.298% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 98.239% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | 93.338% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -1432.841% |
| MannKind Corporation | 721.36 Million USD | 99.08% |
| Ikena Oncology, Inc. | 22.33 Million USD | 70.302% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -217.977% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | 93.534% |
| Gossamer Bio, Inc. | 249.14 Million USD | 97.338% |
| CohBar, Inc. | 1.03 Million USD | -541.714% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | 37.946% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | 65.177% |
| Legend Biotech Corporation | 589.93 Million USD | 98.876% |
| Mural Oncology plc | 37.92 Million USD | 82.512% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 94.999% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -188.978% |
| Disc Medicine, Inc. | 22.87 Million USD | 71.003% |
| Champions Oncology, Inc. | 28.03 Million USD | 76.34% |
| REGENXBIO Inc. | 262.22 Million USD | 97.471% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -97.449% |
| Anavex Life Sciences Corp. | 12.53 Million USD | 47.08% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | 50.617% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | 68.72% |
| Vaxart, Inc. | 34.02 Million USD | 80.506% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | 67.468% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | 76.752% |
| Cellectis S.A. | 249.57 Million USD | 97.342% |
| Longeveron Inc. | 5.33 Million USD | -24.283% |
| Repare Therapeutics Inc. | 41.81 Million USD | 84.139% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 99.724% |
| Inozyme Pharma, Inc. | 60.36 Million USD | 89.012% |
| Revolution Medicines, Inc. | 262.39 Million USD | 97.472% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -214.808% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | 23.105% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | 43.793% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | 52.767% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -208.368% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.871% |
| Denali Therapeutics Inc. | 122.96 Million USD | 94.606% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -19.194% |
| Veru Inc. | 32.81 Million USD | 79.785% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | 3.436% |
| Cingulate Inc. | 10.36 Million USD | 35.98% |
| Passage Bio, Inc. | 39.26 Million USD | 83.106% |
| Context Therapeutics Inc. | 4.19 Million USD | -58.241% |
| Exicure, Inc. | 8.54 Million USD | 22.412% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | 77.521% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | 36.744% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | 69.906% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 95.93% |
| Nuvalent, Inc. | 31.82 Million USD | 79.157% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -4.266% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | 89.475% |
| Unicycive Therapeutics, Inc. | 18 Million USD | 63.15% |
| OmniAb, Inc. | 87.4 Million USD | 92.411% |
| Anew Medical, Inc. | 8.24 Million USD | 19.52% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | 82.677% |
| Lipocine Inc. | 2.63 Million USD | -152.049% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | 74.753% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | 83.505% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | 75.103% |
| G1 Therapeutics, Inc. | 86.15 Million USD | 92.301% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -22.811% |
| Sage Therapeutics, Inc. | 82.74 Million USD | 91.984% |
| Ocugen, Inc. | 23.98 Million USD | 72.343% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | 85.707% |
| Q32 Bio Inc. | 233.12 Million USD | 97.155% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | 26.837% |
| Alumis Inc. Common Stock | 53.5 Million USD | 87.602% |
| Equillium, Inc. | 27.95 Million USD | 76.274% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 96.789% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -17.885% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -8.153% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 95.784% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 90.447% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 33.498% |
| Dominari Holdings Inc. | 4.63 Million USD | -43.107% |
| Edesa Biotech, Inc. | 1.84 Million USD | -260.169% |
| vTv Therapeutics Inc. | 29.56 Million USD | 77.566% |
| Bio-Techne Corporation | 744.34 Million USD | 99.109% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 94.74% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 98.074% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | 83.652% |
| Candel Therapeutics, Inc. | 28.95 Million USD | 77.094% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | 92.818% |
| Nkarta, Inc. | 105.6 Million USD | 93.719% |
| BioCardia, Inc. | 4.59 Million USD | -44.51% |
| Iterum Therapeutics plc | 32.66 Million USD | 79.692% |